Metadoxine: Phase IIb data

A double-blind, crossover, Israeli Phase IIb trial in 36 adults with predominantly inattentive ADHD showed that a single dose of 1,400 mg MG01CI met the primary endpoint of improving mean TOVA ADHD scores from baseline to 4 hours post-dose vs. placebo (mean change of 2 points compared to placebo,

Read the full 495 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE